The Dermatology Digest

JANUARY 14, 2024

The overwhelming majority of people with atopic dermatitis (AD) treated with investigational roflumilast cream 0.15% (Zoryve, Arcutis) showed a measurable improvement in Eczema Area and Severity Index (EASI) in 4 weeks, according to new pooled analyses from two Phase 3 studies. Fully 91.5% Importantly, EASI-90 was observed in 22.4%

Dermatitis 36

Dermatitis Safety Dermatology Hospital 36

The Dermatology Digest

JANUARY 16, 2024

and Sanofi), adding efficacy and safety data for people aged 12 years and older with atopic dermatitis (AD) and uncontrolled moderate-to-severe hand and/or foot involvement. Yancopoulos, MD, PhD, Board Co-Chair, President and Chief Scientific Officer at Regeneron, and a principal inventor of Dupixent, in a news release.

Dermatitis 36

Dermatitis Pharmaceutical Safety Eczema 36

US Dermatologt Partners

MARCH 27, 2024

Improves psoriasis , rosacea , acne , and eczema side effects. Safety and Side Effects This procedure is considered safe. Dr. Charles says, “Any procedure that is still considered emerging or in development will have associated risks because regulations don’t exist yet to ensure safety. Repairs cells and tissues.

Therapy 41

Therapy Treatments Dermatology Collagen 41

The Dermatology Digest

OCTOBER 5, 2023

The DNA Connection Deep in our DNA, there’s a primordial theme of slowing down, connection, and safety, said Dr. Barr. This [can trigger] or exacerbate conditions like psoriasis, acne, and eczema. Essentially a resource is anything that helps you and your patients feel a sense of safety and support.

Safety 36

Safety Social Media Therapy Sun Protection 36

US Dermatologt Partners

JANUARY 7, 2025

Estrogen could also worsen any dark patches and discoloration or make blood vessels more apparent, she added; or it could aggravate skin conditions like eczema and rosacea, said Dr. Debra Jaliman, a dermatologist in New York City. In-office treatments can also help, Dr. Jaliman added. What actually works?

Collagen 36

Collagen Wrinkles Vitamin C Pharmaceutical 36

The Dermatology Digest

MARCH 10, 2025

The IGNITE study was a 24-week, randomized, placebo-controlled, double-blind study to assess the efficacy, safety and tolerability of rocatinlimab monotherapy every four weeks in 769 adults with moderate to severe AD, including patients previously treated with a biologic or systemic Janus kinase (JAK) inhibitor medication. At week 24, 42.3%

Dermatitis 36

Dermatitis Safety Office Eczema 36

The Dermatology Digest

AUGUST 4, 2023

According to Dr. Richard, today she uses many approaches, including biologics (as monotherapy and in combination), as well as phototherapy, to treat patients with psoriasis, eczema, vitiligo, and a “laundry list” of other skin diseases that respond to light. They extrapolated that across 15 million office visits.

Eczema 36

Eczema Private Practice Therapy Dermatitis 36

The Dermatology Digest

FEBRUARY 8, 2024

It has great efficacy and safety and is oral… [This means] no shot and no risk of anaphylaxis.” Upadacitinib’s (Rinvoq, AbbVie) 5-yr safety data show that it is REALLY SAFE and effective in AD, and abrocitinib (Cibinqo, Pfizer) is safe as well.” Hands Up for New CHE therapies Chronic hand eczema (CHE) will also get some love in 2024.

Dermatology 78

Dermatology Eczema Pharmaceutical Dermatitis 78

The Dermatology Digest

FEBRUARY 24, 2025

of children treated with roflumilast cream achieved a 75% improvement in the Eczema Area and Severity Index (EASI-75) at Week 4 compared to 20.6% Safety and tolerability results were consistent with previous trials of roflumilast cream 0.15% in patients aged 6 years with AD. Fully 35.3% for vehicle-treated subjects. of patients.

Eczema 67

Eczema Dermatitis Safety Dermatology 67